Drug Trial Radar · NCT05090280
Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Dec 1, 2021
Primary completion
Apr 26, 2023
Study completion Apr 26, 2023
Sponsor
- Lead sponsor
- Ensysce BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Quotient Sciences; National Institute on Drug Abuse (NIDA)
- First posted
- Oct 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single dose study to assess the pharmacokinetics (PK) of oxycodone, when PF614 is solution is administered alone and with nafamostat as an immediate-release (IR) solution and/or extended-release (ER) capsule prototypes.
Conditions
- Pharmacokinetics
Interventions
PF614 solutionDrug
PF614 solution is an oxycodone prodrug
Naltrexone HydrochlorideDrug
Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.
Nafamostat MesylateDrug
Maximum dose of 10 mg nafamostat co-administered with PF614 solution. Nafamostat will be dosed as an immediate-release (IR) solution or as prototype extended-release (ER) capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic Tmax [Time to Maximum Plasma Concentration]Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
- Pharmacokinetic Cmax [Maximum Plasma Concentration]Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
- Pharmacokinetic C24 [Plasma concentration at 24 hours]Time frame: 24 hours
- Pharmacokinetic AUC [Area Under the Curve]Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
- Pharmacokinetic AUC(0-last)Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
- Pharmacokinetic T1/2 [Half-life]Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.